Answers are grounded in this paper and cite their sources.
Acute lung injury (ALI) is characterized by excessive pulmonary inflammation and lacks effective targeted pharmacotherapies. This study investigated the protective effects of Platycodin D (PLD) in lipopolysaccharide (LPS)-induced ALI and explored the involvement of CD14-associated inflammatory signaling and macrophage phenotypic regulation. Male C57BL/6 mice were challenged with intratracheal LPS and subsequently treated with PLD by inhalation (5 and 10 mg/kg) or intravenous injection (1 and 2 mg/kg), with dexamethasone (5 mg/kg, i.p.) as the positive control. PLD alleviated histopathological lung injury, reduced the lung index, pulmonary MPO levels, neutrophil infiltration, and pro-inflammatory cytokines, and modulated macrophage-associated inflammatory phenotypes. RNA-seq analysis identified prominent regulation of NF-κB and NOD-like receptor signaling. Molecular docking, cellular co-localization, CETSA, and DARTS analysis provided complementary evidence consistent with a possible interaction involving CD14. PLD suppressed TLR4/MyD88/NF-κB signaling and downstream NLRP3 inflammasome-associated responses in both lung tissue and macrophage models. In macrophages, PLD reduced M1-associated markers and increased M2-associated markers. CD14 knockdown altered these inflammatory and polarization responses, supporting a functional contribution of CD14, although PLD retained regulatory effects on several downstream markers after CD14 silencing. Collectively, these findings indicate that PLD attenuates LPS-induced ALI through modulation of CD14-associated inflammatory signaling and macrophage phenotypic regulation. The efficacy observed following both nebulized and intravenous administration provides a basis for further pharmacokinetic and translational evaluation of PLD.
No takes yet. Share an insight, caveat, or question.
LIAO et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: